Literature DB >> 18212301

New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications.

Darren K McGuire1, Silvio E Inzucchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18212301     DOI： 10.1161/CIRCULATIONAHA.107.704080

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  38 in total

Review 1.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

Review 2.  Predicting cardiovascular risk in type 2 diabetes: the heterogeneity challenges.

Authors:  M Odette Gore; Darren K McGuire; Ildiko Lingvay; Julio Rosenstock
Journal:  Curr Cardiol Rep       Date:  2015-07       Impact factor: 2.931

3.  Cardiac ion channel modulation by the hypoglycaemic agent rosiglitazone.

Authors:  J C Hancox
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

4.  Effects of rosiglitazone on the configuration of action potentials and ion currents in canine ventricular cells.

Authors:  N Szentandrássy; G Harmati; L Bárándi; J Simkó; B Horváth; J Magyar; T Bányász; I Lorincz; A Szebeni; V Kecskeméti; P P Nánási
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

5.  Diabetes and heart failure in patients with coronary disease: separating markers from mediators.

Authors:  Darren K McGuire; M Odette Gore; Frederick A Masoudi
Journal:  Diabetes Care       Date:  2010-09       Impact factor: 17.152

Review 6.  Metabolic dysfunction in diabetic cardiomyopathy.

Authors:  Michael Isfort; Sarah C W Stevens; Stephen Schaffer; Chian Ju Jong; Loren E Wold
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

7.  Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.

Authors:  Francisco J Schopfer; Marsha P Cole; Alison L Groeger; Chen-Shan Chen; Nicholas K H Khoo; Steven R Woodcock; Franca Golin-Bisello; U Nkiru Motanya; Yong Li; Jifeng Zhang; Minerva T Garcia-Barrio; Tanja K Rudolph; Volker Rudolph; Gustavo Bonacci; Paul R S Baker; H Eric Xu; Carlos I Batthyany; Y Eugene Chen; Tina M Hallis; Bruce A Freeman
Journal:  J Biol Chem       Date:  2010-01-22       Impact factor: 5.157

8.  5-Arylidenethioxothiazolidinones as inhibitors of tyrosyl-DNA phosphodiesterase I.

Authors:  Venkata Ramana Sirivolu; Sanjeev Kumar V Vernekar; Christophe Marchand; Alena Naumova; Adel Chergui; Amelie Renaud; Andrew G Stephen; Feng Chen; Yuk Y Sham; Yves Pommier; Zhengqiang Wang
Journal:  J Med Chem       Date:  2012-10-08       Impact factor: 7.446

Review 9.  Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes.

Authors:  Cristina Bianchi; Roberto Miccoli; Giuseppe Daniele; Giuseppe Penno; Stefano Del Prato
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

Review 10.  Diabetic cardiomyopathy.

Authors:  Omar Asghar; Ahmed Al-Sunni; Kaivan Khavandi; Ali Khavandi; Sarah Withers; Adam Greenstein; Anthony M Heagerty; Rayaz A Malik
Journal:  Clin Sci (Lond)       Date:  2009-05       Impact factor: 6.124
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.